During their Q4 earnings call, CEO Brian Lian reaffirmed Viking's intention to launch VK2735 as an auto-injector. We do plan to introduce an auto-injector in the Phase 3 program. So we would ...

Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian ...

“The first quarter of 2024 was an exceptional period for Viking,” stated Brian Lian, Ph.D., president and CEO of Viking. “During the quarter, the company reported positive top-line results ...

The data released by Viking showed that adults taking the highest ... effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement. Profit and prosper with the ...

1 "We are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space," said Brian Lian, PhD, CEO of Viking Therapeutics. "We have a long history of working with ...

Viking Therapeutics (VKTX), the developer of ... anticipate will be significant commercial demand,” said Viking CEO Brian Lian in a press release. Despite the news, Viking’s stock fell over ...

interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics.

These API and final finished product capacities are further expandable at Viking's option. "We are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space," ...

Brian Lian, Ph.D., CEO of Viking Therapeutics, expressed confidence in CordenPharma’s ability to meet the anticipated significant commercial demand for VK2735 due to their established presence ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...